Mounjaro®
Starting from £179.99/mo
Start journey Learn moreShort answer: the evidence is reassuring, but there is a practical caveat worth knowing. Semaglutide slows gastric emptying, and for women taking an oral combined or progesterone-only contraceptive pill, that raises a reasonable question about whether absorption is affected. Current NHS guidance suggests no equivalent concern about pill effectiveness with semaglutide — unlike tirzepatide, where the MHRA advises adding a backup method during dose increases. That said, 'no equivalent concern' is not the same as 'no conversation needed'; anyone starting Wegovy (including the new oral semaglutide tablet) should discuss their contraception with a prescriber before they begin. These are prescription-only medicines that require a clinical assessment, a prescriber is best placed to weigh up your individual situation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide works partly by slowing the rate at which food and liquid leave your stomach. That same mechanism is what leads many people to feel full quickly on Wegovy, but it also raises a pharmacokinetic question: if the stomach empties more slowly, could an oral medicine taken at the same time reach the bloodstream in smaller or later amounts?
For oral semaglutide tablets specifically, the SmPC contains a dedicated section on this, because the tablet itself depends on careful absorption conditions. The Wegovy tablet is taken first thing in the morning on an empty stomach with a small amount of plain water, and you wait at least 30 minutes before taking anything else, including other oral medicines. That timing matters. If you take your contraceptive pill at the same moment as the Wegovy tablet, you could interfere with how both are absorbed. Space them by at least that 30-minute window, or discuss moving one of them to a different time of day with your prescriber.
For the weekly injection form of Wegovy, the picture is more settled. NHS England's guidance on weight-management injections does not list a reduction in pill effectiveness as a known concern for semaglutide, in contrast to tirzepatide, where a specific interaction warning exists. That distinction is worth understanding clearly.
The contrast between the two medicines is one of the questions our prescribers field most often. Tirzepatide (Mounjaro) carries a clear MHRA-backed instruction: women using oral contraceptives should add a non-oral backup method (condoms, for example) during the first four weeks of treatment and for four weeks after every dose increase. The reasoning is that tirzepatide's effect on gastric emptying is pronounced enough during that initial period to potentially reduce pill absorption.
Semaglutide does not carry the same dose-escalation-specific instruction. NHS guidance, including NHS Inform Scotland's information on diabetes and weight-loss medicines, notes the contrast explicitly. However, the class-level advice still applies: use effective contraception while you are on any GLP-1 medicine, and plan carefully if pregnancy is a possibility during or after treatment.
This is worth reading about in detail on our dedicated page covering Wegovy and birth control pills, which goes further into the pharmacology for anyone who wants the fuller picture. For women on a progesterone-only pill specifically, there is also a separate consideration covered at our page on Wegovy and the progesterone-only pill.
A few practical steps cover most situations well. First, tell your prescriber which contraceptive pill you take, name and dose if you have it to hand. They will factor that into their assessment. Second, if you are starting on oral semaglutide tablets, pay close attention to timing: the tablet goes first, then a minimum of 30 minutes before other oral medicines. This is not an optional preference, it affects how well both medicines work.
Third, clarify the wash-out period if conception is on the horizon. The MHRA advises a period off treatment before trying to conceive; your prescriber will give you the specific figure based on current guidance and your circumstances. Fourth, if anything changes (a new contraceptive prescription, a dose change, a switch from the injection to the tablet) flag it. Each of those events is worth a brief clinical check.
These are not complicated adjustments. They are the kind of conversation a prescriber has every day, and getting them right at the start is far easier than unpicking problems later. If you have questions about how Wegovy interacts with the pill in your specific situation, our prescribers are available seven days a week. You can also explore what starting treatment with nume actually involves, no referral, no waiting list, and every consultation reviewed by a GPhC-registered Independent Prescriber the same day. For context on what treatment costs, our Wegovy pill cost page sets out what a transparent private prescription includes.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.